Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response as presented at ESMO 2021 will now exceed 18 months – median not yet reached Trial in Progress poster at ASCO outlines the ongoing, randomized Phase 2/3 trial of GRANITE for first-line maintenance treatment of metastatic, MSS-CRC -- EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: G